piggyBac修饰CD19 CAR-T细胞输注后产物源性淋巴瘤的探究
一项1期临床试验评估供者来源CD19 CAR-T细胞治疗异基因造血干细胞移植后复发或持续B细胞恶性肿瘤的疗效。采用piggyBac转座子系统制备CAR-T细胞后,1例患者发生CAR表达CD4+ T细胞淋巴瘤,另1例无症状患者检出第二例CAR-T细胞肿瘤,提示新型基因转移方法需谨慎并定期随访。
要点
- piggyBac制备的CAR-T细胞输注后出现2例CAR-T细胞源性淋巴瘤。
- 首例淋巴瘤转基因组拷贝数高但未插入典型癌基因,存在基因组拷贝数改变及点突变。
- 两例CAR-T细胞源性淋巴瘤均进展,其中1例死亡。
核心结论
- 首次报道2例由CAR基因修饰T细胞衍生的恶性淋巴瘤。
- CAR-T细胞虽安全性记录良好,但新型基因转移方法制备时需警惕并定期随访。
研究设计与样本
- 1期临床试验,评估供者来源CD19特异性CAR-T细胞治疗匹配亲缘异基因造血干细胞移植后复发或持续B细胞恶性肿瘤。
- CAR-T细胞采用piggyBac转座子系统进行基因修饰制备。
主要发现
- 1例患者输注后发生逐渐增大的腹膜后肿瘤,为CAR表达CD4+ T细胞淋巴瘤。
- 筛查其他患者时在1例无症状患者检出胸部主动脉旁淋巴结的第二例CAR-T细胞肿瘤。
- 首例淋巴瘤分析显示转基因拷贝数高,但未插入典型癌基因,存在基因组拷贝数改变和与插入位点无关的点突变。
- 转录组分析显示转基因启动子驱动周围区域转录上调,尽管转基因周围有绝缘序列;全局转录显著变化主要与基因拷贝数相关而非插入位点。
- 两例患者CAR-T细胞源性淋巴瘤均进展,其中1例死亡。
临床怎么用
- 接受CAR-T治疗的患者需定期随访,尤其使用新型基因转移方法制备的基因修饰免疫治疗时。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We performed a phase 1 clinical trial to evaluate outcomes in patients receiving donor-derived CD19-specific chimeric antigen receptor (CAR) T cells for B-cell malignancy that relapsed or persisted after matched related allogeneic hemopoietic stem cell transplant. To overcome the cost and transgene-capacity limitations of traditional viral vectors, CAR T cells were produced using the piggyBac transposon system of genetic modification. Following CAR T-cell infusion, 1 patient developed a gradually enlarging retroperitoneal tumor due to a CAR-expressing CD4+ T-cell lymphoma. Screening of other patients led to the detection, in an asymptomatic patient, of a second CAR T-cell tumor in thoracic para-aortic lymph nodes. Analysis of the first lymphoma showed a high transgene copy number, but no insertion into typical oncogenes. There were also structural changes such as altered genomic copy number and point mutations unrelated to the insertion sites. Transcriptome analysis showed transgene promoter-driven upregulation of transcription of surrounding regions despite insulator sequences surrounding the transgene. However, marked global changes in transcription predominantly correlated with gene copy number rather than insertion sites. In both patients, the CAR T-cell-derived lymphoma progressed and 1 patient died. We describe the first 2 cases of malignant lymphoma derived from CAR gene-modified T cells. Although CAR T cells have an enviable record of safety to date, our results emphasize the need for caution and regular follow-up of CAR T recipients, especially when novel methods of gene transfer are used to create genetically modified immune therapies. This trial was registered at www.anzctr.org.au as ACTRN12617001579381.
引用
- Micklethwaite KP, Gowrishankar K, Gloss BS, et al. Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells. Blood. 2021. PMID: 33974080. doi:10.1182/blood.2021010858
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。